Previous 10 | Next 10 |
home / stock / luv:cc / luv:cc news
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a portfolio of innovative products encompassing transdermal drug delivery applications in the add...
Please see the previously announced news from Starton Therapeutics Inc. VANCOUVER, BC / ACCESSWIRE / November 2, 2022 / LOVE Pharma Co. ("LOVE" and or "The Company")(CSE:LUV)(FSE:G1Q0) , is please to announce an update from its investment in Starton Therapeutics Inc. as the company str...
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics, reports recent developments on Naltrexone’s application for long COVID. A Med...
Naltrexone primarily used to treat alcohol and or opioid has now shown promise in treating Long COVID at low doses 1 Love Pharma announced Letter of Intent to acquire Naltrexone Therapeutics Inc. on 11 October 2022 Naltrexone Therapeutics holds IP for transdermal delivery of Nalt...
VANCOUVER, BC / ACCESSWIRE / October 19, 2022 / LOVE Pharma Co. ("LOVE" or the "Company") (CSE:LUV) (FSE:G1Q0) , is pleased to announce that it has completed its acquisition (the " Acquisition ") ofDoc Hygiene Pharmaceuticals Inc. (" Doc Hygiene ") (as originally disclosed in a press releas...
VANCOUVER, British Columbia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) has provided an update on the launch of its psilocybin trials at John Hopkins University. LOVE Pharma’s wholly owned subsidiary, MicroDoz Therapy, is sponsoring the study to test the effec...
Dr. Albert Garcia Romeu will serve as head researcher for the Love Pharma's MicroDoz sponsored trial to be conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research The MicroDoz Therapy team is sponsoring a study to evaluate the effectiveness of psilocybin in tre...
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) has signed a non-binding Letter of Intent to acquire 100% of Naltrexone Therapeutics Inc., a pharmaceutical technology company with significant IP related to the transdermal delivery of FDA appro...
Love Pharma adding to its addiction treatment portfolio with transdermal IP acquisition for opioid antagonist drug Naltrexone Naltrexone primarily used to treat alcohol and or opioid use disorder and is currently delivered orally which exposes patients to GI related side effects such a...
VANCOUVER, BC / ACCESSWIRE / September 30, 2022 / LOVE Pharma Inc. (" LOVE " or the " Company ") (CSE:LUV) (FSE:G1Q0) is pleased to announce that its subsidiary, Doc Hygiene Pharmaceuticals Inc. (" Doc Hygiene "), has launched operation "Clean Hands" in California, delivering sanitizer pro...
News, Short Squeeze, Breakout and More Instantly...
Love Pharma Inc. Company Name:
LUV:CC Stock Symbol:
CNQC Market:
VANCOUVER, BC, CANADA, May 25, 2023 (GLOBE NEWSWIRE) -- Jolt Health Inc. (formerly Love Pharma Inc.) (“Jolt” and or “the Company”) (CSE:JOLT) (FSE: G1Q0) is pleased to announce that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022...
Toronto, Ontario--(Newsfile Corp. - Le 25 mai/May 2023) - Love Pharma Inc. (LUV) has announced a name and symbol change to Jolt Health Inc. (JOLT). Shares will begin trading under the new name and symbol and with a new CUSIP number on May 26, 2023. Disclosure documents are available at ww...
VANCOUVER, BC, CANADA, May 16, 2023 (GLOBE NEWSWIRE) -- LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0) is pleased to announce that it has changed its name to “Jolt Health Inc.”. The board of directors of the Company approve...